{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:27:11Z","timestamp":1792301231242,"version":"4.4.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:italic>Ebolavirus<\/jats:italic> (EBOV) is a virulent pathogen that causes Ebola virus disease (EVD), which is a life-threatening human condition with a fatality rate of up to 90%. Since the first outbreak in Africa in 1976, several outbreaks and epidemics of EBOV have occurred across the globe. While EVD is recognized as a serious threat to human health and outbreaks occur almost every year, the treatment options for the disease are limited. In designing therapeutic strategies against EBOV infection, viral structural proteins, such as glycoprotein (GP), could be an excellent target for neutralizing the virus. According to the latest research, GP-specific antibodies are the most efficient post-exposure treatments for EVD. Ansuvimab-zykl, i.e., mAb114 (Ebanga\u2122), is a recent FDA-approved human immunoglobulin monoclonal antibody targeting EBOV GP. This review provides a brief overview of the pharmacological effects and safety profile of ansuvimab in clinical trials and provides insights into the precise mechanism of this new drug for treating EVD.<\/jats:p>","DOI":"10.3389\/fphar.2023.1083429","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T04:48:46Z","timestamp":1678250926000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["Ebanga\u2122: The most recent FDA-approved drug for treating Ebola"],"prefix":"10.3389","volume":"14","author":[{"given":"Elahe","family":"Taki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roya","family":"Ghanavati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahereh","family":"Navidifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Dashtbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Heidary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Moghadamnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/ajhp\/zxab092","article-title":"Infusion-associated HRI. AHFS\u00ae first Release\u2122","volume":"78","author":"Authors Anonymous","year":"2021","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41587-019-0284-y","article-title":"New antibodies best ZMapp in Ebola trial","volume":"37","author":"Authors Anonymous","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"S528","DOI":"10.1093\/infdis\/jiy333","article-title":"Vaccine generation of protective Ebola antibodies and identification of conserved B-cell signatures","volume":"218","author":"Cagigi","year":"2018","journal-title":"J. Infect. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nature10348","article-title":"Ebola virus entry requires the cholesterol transporter Niemann\u2013Pick C1","volume":"477","author":"Carette","year":"2011","journal-title":"Nat"},{"key":"B5","unstructured":"2014-2016 Ebola outbreak in West Africa2014"},{"key":"B6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.coph.2021.07.020","article-title":"Therapeutics development for Ebola virus disease: A recent scenario","volume":"60","author":"Chakraborty","year":"2021","journal-title":"Cur Opin. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1017\/S0950268816000054","article-title":"Persistence of Ebola virus in various body fluids during convalescence: Evidence and implications for disease transmission and control","volume":"144","author":"Chughtai","year":"2016","journal-title":"Epidemiol. Infect."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10081213","article-title":"The evolution of medical countermeasures for Ebola virus disease: Lessons learned and next steps","volume":"10","author":"Crozier","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41579-020-0354-7","article-title":"Viral genomics in Ebola virus research","volume":"18","author":"Di Paola","year":"2020","journal-title":"Nat. Rev. Microbiol."},{"key":"B11","unstructured":"Prescribing information. Ridgeback Biotherapeutics, LP2020"},{"key":"B12","unstructured":"FDA approves first treatment for Ebola virus2020"},{"key":"B13","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(10)60667-8","article-title":"Ebola haemorrhagic fever","volume":"377","author":"Feldmann","year":"2011","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3390\/microorganisms9030566","article-title":"Formulation, stability, pharmacokinetic, and modeling studies for tests of synergistic combinations of orally available approved drugs against Ebola virus in vivo","volume":"9","author":"Finch","year":"2021","journal-title":"Microorganism"},{"key":"B15","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0140-6736(19)30036-4","article-title":"Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): An open-label phase 1 study","volume":"393","author":"Gaudinski","year":"2019","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.coph.2021.06.010","article-title":"Genome structure and genetic diversity in the Ebola virus","volume":"60","author":"Ghosh","year":"2021","journal-title":"Cur Opin. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41564-018-0227-2","article-title":"The discovery of Bombali virus adds further support for bats as hosts of ebolaviruses","volume":"3","author":"Goldstein","year":"2018","journal-title":"Nat. Microbiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-020-0147-3","article-title":"Ebola virus disease","volume":"6","author":"Jacob","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.14744\/nci.2015.97269","article-title":"An overview of Ebola virus disease","volume":"2","author":"Kadanali","year":"2015","journal-title":"North Clin. Istanb"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.3390\/v4112471","article-title":"Niemann-Pick C1 (NPC1)\/NPC1-like1 chimeras define sequences critical for NPC1's function as a flovirus entry receptor","volume":"4","author":"Krishnan","year":"2012","journal-title":"Viruses"},{"key":"B21","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s40265-021-01483-4","article-title":"Ansuvimab: First approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"key":"B22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature07082","article-title":"Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor","volume":"454","author":"Lee","year":"2008","journal-title":"Nat"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1056\/NEJMe1915350","article-title":"Monoclonal antibody therapy for Ebola virus disease","volume":"381","author":"Levine","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3390\/v14030579","article-title":"Therapeutic strategies against Ebola virus infection","volume":"14","author":"Liu","year":"2022","journal-title":"Viruses"},{"key":"B25","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S0140-6736(18)33132-5","article-title":"Ebola virus disease","volume":"393","author":"Malvy","year":"2019","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/nyas.14519","article-title":"Presence of Ebola virus in breast milk and risk of mother\u2010to\u2010child transmission: Synthesis of evidence","volume":"1488","author":"Medina-Rivera","year":"2021","journal-title":"Ann. N. Acad. Sci."},{"key":"B27","first-page":"20","article-title":"What\u2019s new in children\u2019s drugs","volume":"38","author":"Meyers","year":"2021","journal-title":"Contemp. Pediatr."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1126\/science.aad6117","article-title":"Structural and molecular basis for Ebola virus neutralization by protective human antibodies","volume":"351","author":"Misasi","year":"2016","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.immuni.2021.01.015","article-title":"Immunotherapeutic strategies to target vulnerabilities in the Ebolavirus glycoprotein","volume":"54","author":"Misasi","year":"2021","journal-title":"Immun"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1056\/NEJMc2113505","article-title":"Antibody use during an outbreak of Ebola virus disease in the democratic republic of Congo, 2020","volume":"386","author":"Mulangu","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B32","volume-title":"Drugs and lactation database (LactMed)","year":"2006"},{"key":"B33","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1146\/annurev-pathol-020712-164041","article-title":"Pathogenesis of the viral hemorrhagic fevers","volume":"8","author":"Paessler","year":"2013","journal-title":"Annu. Rev. Pathol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nat"},{"key":"B35","unstructured":"EBANGA (ansuvimab-zykl): US prescribing information2021"},{"key":"B36","unstructured":"New eBook: Your guide to quality drug data2021"},{"key":"B37","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jiph.2022.01.005","article-title":"A systematic review of Ebola virus disease outbreaks and an analysis of the efficacy and safety of newer drugs approved for the treatment of Ebola virus disease by the US Food and Drug Administration from 2016 to 2020","volume":"15","author":"Sivanandy","year":"2022","journal-title":"J. Infect. Public Health"},{"key":"B38","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nm1080","article-title":"An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus","volume":"10","author":"Traggiai","year":"2004","journal-title":"Nat. Med."},{"key":"B39","unstructured":"Drug trials snapshots: INMAZEB2022"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1007\/s12250-021-00454-z","article-title":"Identification and characterization of a novel single domain antibody against Ebola virus","volume":"36","author":"Wang","year":"2021","journal-title":"Virol. Sin."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1126\/science.287.5458.1664","article-title":"Epitopes involved in antibody-mediated protection from Ebola virus","volume":"287","author":"Wilson","year":"2000","journal-title":"Science"},{"key":"B42","volume-title":"Ebola virus disease","year":"2020"},{"key":"B43","unstructured":"Ebola virus disease2022"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1083429\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T04:48:55Z","timestamp":1678250935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1083429\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":43,"alternative-id":["10.3389\/fphar.2023.1083429"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1083429","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,8]]},"article-number":"1083429"}}